Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Mundipharma, Swissmedic

Mundipharma welcomes the news that Swissmedic (the Swiss Agency for Therapeutic Products; the surveillance authority for medicines and medical devices in Switzerland) is conducting a fast-track review of Mundipharma Switzerland’s application to extend marketing authorisation for the SGLT2 inhibitor canagliflozin as an adjunct to the standard of care in adults with type 2 diabetes mellitus (T2DM) and stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria.

10.10.2019 - 01:02:21

Mundipharma: Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana® in fast-track procedure

Last accessed September 2019.

Job code: MBL/DIAB-19029
Date of preparation: October 2019

@ businesswire.com